OGN

NEUTRALM&A

Organon & Co.

2026-08-06

Price

$13.55

-0.07%

This is the 2026-08-06 snapshot — the signals and analysis for OGN as of this single trading day.

View full OGN research hub →

Score14.5Top Tier

Signals6/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 6

Volume0.6xvs 20d avg

Analysis

Organon's (OGN) uniquely low volatility and steady price action are entirely anchored by its pending $14-per-share all-cash acquisition by Sun Pharma. Despite a recent Q2 EPS miss, the stock remains pinned near 52-week highs, demonstrating classic institutional merger arbitrage behavior where fundamental performance is secondary to deal completion probability. The current RISK_ON macro regime, characterized by exceptionally tight credit spreads, provides high market confidence in deal financing, explaining the stock's resilient, low-stress drift toward the buyout price.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSELLER FATIGUE

Key Takeaways

Actionable Thesis: OGN is currently a pure merger arbitrage play, offering a low-volatility, ~3.3% spread to the $14/share Sun Pharma acquisition price.
Key Risk: Regulatory pushback, antitrust scrutiny, or timeline delays pushing past the expected early-2027 close could widen the current deal spread.
What to Watch: Keep an eye on shareholder votes and regulatory approval milestones, as traditional fundamental catalysts like earnings have been neutralized.

← Back to 2026-08-06 View Full OGN History →Yahoo Finance &nearr;